Literature DB >> 20730571

Immunohistochemical evidence for the over-expression of Glutathione peroxidase 3 in clear cell type ovarian adenocarcinoma.

Hee Joong Lee1, Jin Hwan Do, Sumi Bae, Sanghwa Yang, Xianglon Zhang, Ahwon Lee, Young Jin Choi, Dong Choon Park, Woong Shick Ahn.   

Abstract

Glutathione peroxidase 3 (GPX3) is a member of glutathione peroxidase family, exerting one of the most important cellular defense mechanisms against stress signals, including oxidative damage. In this study, the expression of GPX3 mRNA and protein was analyzed for ovarian cancer tissues to test its applicability as a biomarker that can distinguish the four major histologic types of epithelial ovarian cancer. A public microarray dataset containing 99 ovarian cancer and 4 normal ovary samples was downloaded, and GPX3 mRNA expression was analyzed. The expression of GPX3 protein was measured by immunohistochemical staining in 40 epithelial ovarian cancer tissues, 10 for each of the serous, endometrioid, mucinous, and clear cell type. Histoscores were made from the immunohistostaining, and analysis of variance (ANOVA) was performed to quantitate the differences in protein level. Analysis of genomic dataset confirms a GPX3 overexpression in clear cell type ovarian adenocarcinoma compared with normal ovary and 3 other subtypes of epithelial ovarian cancer at mRNA level. GPX3 also shows the highest average antibody staining intensities in clear cell type ovarian adenocarcinomas over the other 3 types in immunostaining on tissue arrays. This is the first validation of GPX3 as a clear cell type-specific biomarker in ovarian cancer patients' tissues by immunostaining. GPX3 may serve as an important molecular marker for the diagnosis and molecular understanding of clear cell carcinoma of the ovary.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20730571     DOI: 10.1007/s12032-010-9659-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

1.  Coordinately up-regulated genes in ovarian cancer.

Authors:  C D Hough; K R Cho; A B Zonderman; D R Schwartz; P J Morin
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

Review 2.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

Review 3.  The role of gene expression profiling in the clinical management of ovarian cancer.

Authors:  R I Olivier; M van Beurden; L J van' t Veer
Journal:  Eur J Cancer       Date:  2006-10-18       Impact factor: 9.162

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 5.  Glutathione peroxidases and redox-regulated transcription factors.

Authors:  Regina Brigelius-Flohé
Journal:  Biol Chem       Date:  2006 Oct-Nov       Impact factor: 3.915

6.  Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.

Authors:  T Sugiyama; T Kamura; J Kigawa; N Terakawa; Y Kikuchi; T Kita; M Suzuki; I Sato; K Taguchi
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

Review 7.  Selenium and endocrine systems.

Authors:  Geoffrey J Beckett; John R Arthur
Journal:  J Endocrinol       Date:  2005-03       Impact factor: 4.286

8.  DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma.

Authors:  D F Peng; M Razvi; H Chen; K Washington; A Roessner; R Schneider-Stock; W El-Rifai
Journal:  Gut       Date:  2008-07-29       Impact factor: 23.059

9.  Novel biomarker candidates for gastric cancer.

Authors:  Sanghwa Yang; Hyun Cheol Chung
Journal:  Oncol Rep       Date:  2008-03       Impact factor: 3.906

10.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.

Authors:  Donald R Schwartz; Sharon L R Kardia; Kerby A Shedden; Rork Kuick; George Michailidis; Jeremy M G Taylor; David E Misek; Rong Wu; Yali Zhai; Danielle M Darrah; Heather Reed; Lora H Ellenson; Thomas J Giordano; Eric R Fearon; Samir M Hanash; Kathleen R Cho
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

View more
  7 in total

1.  Effects of Weight Loss on Glutathione Peroxidase 3 Serum Concentrations and Adipose Tissue Expression in Human Obesity.

Authors:  Julia Langhardt; Gesine Flehmig; Nora Klöting; Stefanie Lehmann; Thomas Ebert; Matthias Kern; Michael R Schön; Daniel Gärtner; Tobias Lohmann; Miriam Dressler; Mathias Fasshauer; Peter Kovacs; Michael Stumvoll; Arne Dietrich; Matthias Blüher
Journal:  Obes Facts       Date:  2018-12-11       Impact factor: 3.942

2.  Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma.

Authors:  Hiroshi Kobayashi; Hitomi Sugimoto; Shunsuke Onishi; Kazutoshi Nakano
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

3.  Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.

Authors:  Jean-Pierre Gillet; Anna Maria Calcagno; Sudhir Varma; Ben Davidson; Mari Bunkholt Elstrand; Ram Ganapathi; Aparna A Kamat; Anil K Sood; Suresh V Ambudkar; Michael V Seiden; Bo R Rueda; Michael M Gottesman
Journal:  Clin Cancer Res       Date:  2012-04-05       Impact factor: 12.531

4.  Hypoxia-induced Maspin Expression Affects the Prognosis of Ovarian Clear Cell Carcinoma.

Authors:  Eun Ji Lee; Soo Jin Park; Cheol Lee; Ga Won Yim; Jae Weon Kim; Hee Seung Kim
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

5.  Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression.

Authors:  Deep Agnani; Olga Camacho-Vanegas; Catalina Camacho; Shashi Lele; Kunle Odunsi; Samantha Cohen; Peter Dottino; John A Martignetti
Journal:  J Ovarian Res       Date:  2011-10-22       Impact factor: 4.234

6.  GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment.

Authors:  Beth L Worley; Yeon Soo Kim; Jennifer Mardini; Rameez Zaman; Kelly E Leon; Piyushi Gupta Vallur; Asvelt Nduwumwami; Joshua I Warrick; Patrick F Timmins; Joshua P Kesterson; Rébécca Phaëton; Nam Y Lee; Vonn Walter; Lauren Endres; Karthikeyan Mythreye; Katherine M Aird; Nadine Hempel
Journal:  Redox Biol       Date:  2018-11-17       Impact factor: 11.799

7.  CancerMA: a web-based tool for automatic meta-analysis of public cancer microarray data.

Authors:  Julia Feichtinger; Ramsay J McFarlane; Lee D Larcombe
Journal:  Database (Oxford)       Date:  2012-12-15       Impact factor: 3.451

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.